Ï㽶ÊÓƵ

Kevin Byrne
No Rating Available
(Learn About Our Rating System)

Kevin Byrne, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City

  • Kevin Byrne, MD, Assistant Professor (Clinical), earned his medical degree at Boston Ï㽶ÊÓƵ School of Medicine. He completed Adult Psychiatry residency at the Ï㽶ÊÓƵ of Utah Spencer Fox Eccles School of Medicine where he served as Chief Resident. He is board certified in Psychiatry by the ABPN. Dr. Byrne's clinical interests include psychiatric care for people with cancer, existential distress, psychedelic treatments for mental health, treatment-resistant mood disorders, trauma and its related conditions, and advanced psychopharmacology. His research focuses on examining psychedelic treatments such as ketamine, MDMA, and psilocybin for the treatment of existential distress and other mental health conditions. Dr. Byrne is excited to be continuing his work as a member of the outpatient teams at the Ï㽶ÊÓƵ of Utah Huntsman Mental Health Institute and at the Huntsman Cancer Hospital.

    Specialties

    Board Certification

    American Board of Psychiatry & Neurology (Psychiatry)

  • Kevin Byrne, MD, Assistant Professor (Clinical), earned his medical degree at Boston Ï㽶ÊÓƵ School of Medicine. He completed Adult Psychiatry residency at the Ï㽶ÊÓƵ of Utah Spencer Fox Eccles School of Medicine where he served as Chief Resident. He is board certified in Psychiatry by the ABPN. Dr. Byrne's clinical interests include psychiatric care for people with cancer, existential distress, psychedelic treatments for mental health, treatment-resistant mood disorders, trauma and its related conditions, and advanced psychopharmacology. His research focuses on examining psychedelic treatments such as ketamine, MDMA, and psilocybin for the treatment of existential distress and other mental health conditions. Dr. Byrne is excited to be continuing his work as a member of the outpatient teams at the Ï㽶ÊÓƵ of Utah Huntsman Mental Health Institute and at the Huntsman Cancer Hospital.

    Board Certification and Academic Information

    Academic Departments Psychiatry -Primary
    Academic Divisions Adult Psychiatry
    Board Certification
    American Board of Psychiatry & Neurology (Psychiatry)

    Education history

    Residency Adult Psychiatry - Ï㽶ÊÓƵ of Utah Spencer Fox Eccles School of Medicine Chief Resident
    Residency Adult Psychiatry - Ï㽶ÊÓƵ of Utah Spencer Fox Eccles School of Medicine Resident
    Professional Medical Medicine - Boston Ï㽶ÊÓƵ School of Medicine M.D.
    Undergraduate Computer Science - Pomona College B.A.

    Selected Publications

    Journal Article

    1. Lewis BR, Garland EL, Byrne K, Durns T, Hendrick J, Beck A, Thielking P (2023). HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. J Pain Symptom Manage, 66(3), 258-269. ()
    2. Lewis BR, Byrne K, Hendrick J, Garland EL, Thielking P, Beck A (2023). Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial. J Psychedelic Stud. ()
    3. Byrne KJ, Lindsay S, Baker N, Schmutz C, Lewis B (2023). In naturalistic psychedelic use, group use is common and acceptable. J Psychedelic Stud. ()
    4. Turner DC, Edmiston AM, Zohner YE, Byrne KJ, Seigfreid WP, Girkin CA, Morris JS, Downs JC (2019). Transient Intraocular Pressure Fluctuations: Source, Magnitude, Frequency, and Associated Mechanical Energy. Invest Ophthalmol Vis Sci, 60(7), 2572-2582. ()
    5. Keefe KR, Byrne KJ, Levi JR (2018). Treating pediatric post-tonsillectomy pain and nausea with complementary and alternative medicine. Laryngoscope, 128(11), 2625-2634. ()
    6. Fowler ML, Zhu C, Byrne K, Lieber SB, Moore A, Shmerling RH, Paz Z (2017). Pathogen or contaminant? Distinguishing true infection from synovial fluid culture contamination in patients with suspected septic arthritis. Infection, 45(6), 825-830. ()

    Review

    1. Lewis BR, Byrne K (2023). A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder. [Review]. Focus (Am Psychiatr Publ), 21(3), 247-256. ()
    2. Lewis BR, Byrne K (2021). Is MDD the right target for early-stage psychedelic-assisted therapy trials? [Review]. J Psychedelic Stud, 5(2), 65-68. ()

  • News & Podcasts

    News